Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of ($0.01), $0.08 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $290.4 million versus the consensus estimate of $276.75 million.

GUIDANCE:

Tandem Diabetes sees FY2026 revenue of $1.065-1.085 billion, versus the consensus of $1.102 billion.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.